CONTRAINDICATIONS

Nucleofill must not be administered directly in the periocular area (eyelids, eye socket) or directly into blood or lymphatic vessels.
Nucleofill must not be used in patients with cardiovascular diseases, persistent skin inflammation, epilepsy, diabetes, active herpes virus infection, infectious skin diseases, previous or current autoimmune diseases, severe allergies, persistent inflammatory conditions, or known hypersensitivity to any of the ingredients of the product.
Nucleofill must not be used in pregnant or breastfeeding women.
Nucleofill must not be used in individuals under 18 years of age.
Do not mix with other preparations.
Swelling or pigmentation changes of the skin may occur.
In patients taking acetylsalicylic acid, petechiae (small bruises) may appear.
Patients using anticoagulant medication should discontinue use at least 14 days prior to the administration of Nucleofill.
Store the product out of the reach of children.

ADVERSE REACTIONS

After administration of Nucleofill, certain side effects related to the injection may occur.

These reactions include swelling and, in some cases, temporary bruising, which usually resolve within a few hours.
Occasionally, mild edema may occur, which disappears within a few days.
Particular caution should be exercised when performing procedures in the eye area.

IMPORTANT: Patients should report any adverse reactions to their physician, even those not listed in the instructions for use.

Dermatic Sp. z o.o.
ul. Chartowo 5 61-245 Poznań (Polen)
Steuer-IdNr. 782 256 84 40

tel: +49 3052014470
e-mail: info@hyaloo.de